Twenty-four-hour treatment options are increasingly used in Parkinson's disease (PD) as part of continuous drug delivery strategy to aid concordance and reduce motor complications. However, 24h apomorphine therapy in advanced PD is beneficial but often not attempted because of nodule formation and tolerability issues as well as cost implications.To extend the beneficial effect of 12–14h waking day apomorphine infusion to 24h therapy by combining with Rotigotine transdermal patch therapy and assess motor and non-motor effects over a follow up period of 2 years.15 PD patients (mean age 60.3±11.3 years; disease duration 15.3±4.8 years) on 14h apomorphine infusion were additionally treated with transdermal Rotigotine patch (mean dose 9.3±4.3mg) used overnight and continue to use this at 2 years follow up. Motor (Unified Parkinson's Disease Rating Scale part 3), non-motor (NMSS), sleep (sleep domain of NMSS) and quality of life (PDQ-8) measures were assessed as part of routine clinical practice.There was a significant improvement in all outcome measures at 2 years with good tolerability. In particular significant improvements were noted and sustained at 2 years in relation to sleep/fatigue and mood/apathy domains of NMSS.Combining apomorphine infusion with Rotigotine patch appears to be a useful of way of extending the beneficial effects of infusion with good tolerability and improved aspects of sleep and mood sustained at 2 years in advanced PD. Larger randomized study would be of use.